Immunotherapy News and Research

Latest Immunotherapy News and Research

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.

7 Jun 2016

Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.

7 Jun 2016

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.

7 Jun 2016

Combination immunotherapy may be better than one to combat metastatic melanoma

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one.

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Researchers at the University of Rochester Wilmot Cancer Institute discovered something simple and inexpensive to reduce neuropathy in hands and feet due to chemotherapy--exercise.

6 Jun 2016

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found.

6 Jun 2016

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Patients who don't respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology on June 4 in Chicago.

6 Jun 2016

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

For seven months, three-year-old Emil Abbasov underwent chemotherapy to fight the tangerine-sized, cancerous tumor growing in his abdomen. But each time, the tumor resisted harder. Each time, he felt more side effects.

6 Jun 2016

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

Stimulating STING pathway to provoke life-extending immune response shows promise in AML

A protein known as STING plays a crucial role in the immune system's ability to "sense" cancer by recognizing and responding to DNA from tumor cells. Injection of compounds that activate the STING pathway directly into solid tumors in mice has been shown in prior studies to result in very potent anti-tumor immune responses.

3 Jun 2016

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.

3 Jun 2016

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Cancer immunotherapies--drugs that work by making a patient's immune system better at spotting and destroying tumor cells--are increasingly generating headlines. A number of these drugs are now being used for the treatment of melanoma, lung, and kidney cancers, and are showing promise in clinical trials with other diseases as well.

3 Jun 2016

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.

2 Jun 2016

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany.

2 Jun 2016

Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Researchers should include laboratory mice that are old and obese in their studies of immunotherapy treatments for cancer, according to a review article by Saint Louis University scientists.

2 Jun 2016

Brain scan combined with long-term memory test could help early Alzheimer's diagnosis

People with Alzheimer's disease could benefit from earlier diagnosis if a long-term memory test combined with a brain scan were carried out, a study suggests.

1 Jun 2016

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach in a paper, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient," that will be published online May 30 in The Journal of Experimental Medicine.

30 May 2016

Immunotherapy News and Research

Latest Immunotherapy News and Research

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

Combination immunotherapy may be better than one to combat metastatic melanoma

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Stimulating STING pathway to provoke life-extending immune response shows promise in AML

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Brain scan combined with long-term memory test could help early Alzheimer's diagnosis

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in